- Home
- NCI vs SILO Comparison
NCI vs SILO Comparison
Compare NCI & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- SILO
- Stock Information
- Founded
- NCI 1992
- SILO 2010
- Country
- NCI Hong Kong
- SILO United States
- Employees
- NCI N/A
- SILO N/A
- Industry
- NCI
- SILO Apparel
- Sector
- NCI
- SILO Consumer Discretionary
- Exchange
- NCI NYSE
- SILO Nasdaq
- Market Cap
- NCI 10.1M
- SILO 8.8M
- IPO Year
- NCI 2024
- SILO N/A
- Fundamental
- Price
- NCI $0.56
- SILO $1.61
- Analyst Decision
- NCI
- SILO
- Analyst Count
- NCI 0
- SILO 0
- Target Price
- NCI N/A
- SILO N/A
- AVG Volume (30 Days)
- NCI 352.1K
- SILO 9.1M
- Earning Date
- NCI 12-19-2024
- SILO 02-14-2025
- Dividend Yield
- NCI N/A
- SILO N/A
- EPS Growth
- NCI N/A
- SILO N/A
- EPS
- NCI 0.08
- SILO N/A
- Revenue
- NCI $22,481,862.00
- SILO $72,102.00
- Revenue This Year
- NCI N/A
- SILO $1.86
- Revenue Next Year
- NCI N/A
- SILO N/A
- P/E Ratio
- NCI $7.39
- SILO N/A
- Revenue Growth
- NCI N/A
- SILO N/A
- 52 Week Low
- NCI $0.35
- SILO $0.77
- 52 Week High
- NCI $11.39
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- SILO 53.40
- Support Level
- NCI N/A
- SILO $1.50
- Resistance Level
- NCI N/A
- SILO $1.89
- Average True Range (ATR)
- NCI 0.00
- SILO 0.20
- MACD
- NCI 0.00
- SILO -0.04
- Stochastic Oscillator
- NCI 0.00
- SILO 28.81
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company whose a one-stop apparel solution services provider. It offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European, and North American markets through Neo-Concept HK.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.